DigestRedComo funciona
Red
/
Empresas
Ar
No verificado

Arialys Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaPsiquiatríaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
25/09/2025
Industria
Psiquiatría
Salud
VIH, SIDA y enfermedades autoinmunes
Farmacéutica
Biotecnología
Arialys Therapeutics Receives FDA Rare Pediatric Disease Designation for ART5803 to Treat Anti-NMDA Receptor Encephalitis
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0
17/06/2025
Psiquiatría
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Industria
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0
26/02/2025
Biotecnología
Sanidad
Salud
Farmacéutica
Psiquiatría
Ciencia
Medicina - Varios
Industria
Arialys Therapeutics Initiates MAD Cohorts Having Completed All Planned SAD Cohorts in a Phase 1 Study of ART5803 for the Treatment of Autoimmune Neuropsychiatric Disease
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0
22/10/2024
Mercado laboral
Psiquiatría
Ciencia
Biotecnología
Sanidad
Salud
Farmacéutica
Arialys Therapeutics Appoints Sankalp Gokhale, M.D., Chief Medical Officer
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0
10/10/2024
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0
25/06/2024
Biotecnología
Psiquiatría
Salud
Farmacéutica
Mercado laboral
Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and Chief Executive Officer
Fuente
Arialys Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0